檢索結果 - Jang IJ

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects 由 Kim E, Park KR, Jang IJ, Yu KS, Lee S

    發表在 Drug Design, Development and Therapy (2019-11-01)
    獲取全文
    Article


  2. 2

    Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined si... 由 Kim S, Lee S, Cho JY, Yoon SH, Jang IJ, Yu KS

    發表在 Drug Design, Development and Therapy (2017-11-01)
    獲取全文
    Article


  3. 3

    Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects 由 Koh J, Khwarg J, Yu KS, Lee S, Jang IJ, Lee S

    發表在 Drug Design, Development and Therapy (2025-09-01)
    獲取全文
    Article


  4. 4

    Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in he... 由 Rhee SJ, Lee S, Yoon SH, Cho JY, Jang IJ, Yu KS

    發表在 Drug Design, Development and Therapy (2016-04-01)
    獲取全文
    Article


  5. 5

    Safety, Tolerability and Pharmacokinetics of Intravenous Sodium Taurodeoxycholate, HY209, a GPCR19 Agonist Inhibiting Inflammasomal Activation 由 Chung WK, Jeon I, Jang IJ, Seong SY, Han SA, Yu KS

    發表在 Drug Design, Development and Therapy (2024-12-01)
    獲取全文
    Article


  6. 6

    Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers 由 Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ

    發表在 Drug Design, Development and Therapy (2014-01-01)
    獲取全文
    Article


  7. 7

    Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subje... 由 Ryu H, Kim HC, Jeon I, Jang IJ, Cho JY, Kim KT, Oh J

    發表在 Drug Design, Development and Therapy (2024-07-01)
    獲取全文
    Article


  8. 8

    Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects 由 Kim HC, Yang E, Ban MS, Kim YK, Hong SH, Jung J, Jang IJ, Lee S

    發表在 Drug Design, Development and Therapy (2023-04-01)
    獲取全文
    Article


  9. 9

    A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in hea... 由 Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS

    發表在 Drug Design, Development and Therapy (2015-02-01)
    獲取全文
    Article


  10. 10

    Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state 由 Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H

    發表在 Drug Design, Development and Therapy (2014-06-01)
    獲取全文
    Article


  11. 11

    Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects 由 Khwarg J, Lee S, Jang IJ, Kang WH, Lee HJ, Kim KY, Jeong KS, Won C, Choi YW, Ha DC, Jung R, Han MG, Jung WT, Nam KY, Kim YS, Yu KS, Oh J

    發表在 Drug Design, Development and Therapy (2024-02-01)
    獲取全文
    Article


檢索工具: